6533b82cfe1ef96bd128f58b
RESEARCH PRODUCT
Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms
Barbara ParrinoPaola BarrajaVirginia SpanòPatrizia DianaGirolamo CirrincioneAlessandra MontalbanoDomenico SchillaciStella CascioferroAnna Carbonesubject
0301 basic medicineImipenemmedicine.drug_classAvibactam030106 microbiologyAntibioticsDrug resistancePharmacologyBiologySettore BIO/19 - Microbiologia Generalemedicine.disease_causeMicrobiology03 medical and health scienceschemistry.chemical_compoundAntibiotic resistanceDrug DiscoverymedicineHumansPseudomonas InfectionsBeta-Lactamase InhibitorsPseudomonas aeruginosaDrug Discovery3003 Pharmaceutical ScienceEnterobacteriaceae InfectionsDrug Resistance MicrobialSettore CHIM/08 - Chimica FarmaceuticaImipenemchemistryMolecular Medicine; Drug Discovery3003 Pharmaceutical ScienceMolecular MedicineEffluxbeta-Lactamase InhibitorsAzabicyclo Compoundsmedicine.drugdescription
There is urgent need for new therapeutic strategies to fight the global threat of antibiotic resistance. The focus of this Perspective is on chemical agents that target the most common mechanisms of antibiotic resistance such as enzymatic inactivation of antibiotics, changes in cell permeability, and induction/activation of efflux pumps. Here we assess the current landscape and challenges in the treatment of antibiotic resistance mechanisms at both bacterial cell and community levels. We also discuss the potential clinical application of chemical inhibitors of antibiotic resistance mechanisms as add-on treatments for serious drug-resistant infections. Enzymatic inhibitors, such as the derivatives of the β-lactamase inhibitor avibactam, are closer to the clinic than other molecules. For example, MK-7655, in combination with imipenem, is in clinical development for the treatment of infections caused by carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa, which are difficult to treat. In addition, other molecules targeting multidrug-resistance mechanisms, such as efflux pumps, are under development and hold promise for the treatment of multidrug resistant infections.
year | journal | country | edition | language |
---|---|---|---|---|
2017-06-09 | Journal of Medicinal Chemistry |